Name | 4basebio |
---|---|
Epic | 4BB |
Isin | GB00BMCLYF79 |
Index | MID300 |
Industry | Pharmaceuticals & Biotechnology |
Latest share price | 1,316.67p | Net gearing | n/a |
---|---|---|---|
Market capitalisation | £203.79 | Debt ratio | n/a |
Shares in issue | 12.81 | Debt-to-equity ratio | n/a |
P/E ratio | n/a | Assets / equity ratio | n/a |
Total dividends per share | n/a | Price to book value | n/a |
Dividend yield | n/a | ROCE | -69.97 |
Dividend cover | n/a | EPS growth | n/a |
Earning per share | -42 | 52-week high / low | 545.00p / 1,820.00p |
Type | Ex-date | Pay-date | Net-dividend |
---|---|---|---|
No dividends declared |
Company name | 4basebio |
---|---|
Address | 25 Norman Way, Over, Cambridge, United Kingdom, CB24 5QE |
Telephone | +44 (0)1223 967943 |
Website | http://www.4basebio.com/ |
Director | Position |
---|---|
Dr Heikki Lanckriet | CEO |
Mr David John Roth | CFO |
Mr Hansjörg Plaggemars | Non-Executive Director |
Mr Joseph Manuel Fernández | Non-Executive Director |
Mr Timothy Paul McCarthy | Non-Executive Chairman |
Mr Maria Del Pilar de la Huerta | Independent Non-Executive Director |
Assets £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
Intangible asssets and goodwill | 2.12 | 1.27 | 0.79 |
Investments and other non-current assets | n/a | n/a | n/a |
Total non-current assets | 5.79 | 4.06 | 2.3 |
Inventory / work in progress | 0.13 | 0.16 | 0.13 |
Trade and other receivables | 0.05 | 0.05 | 0.04 |
Cash and equivalents | 4.35 | 9.59 | 15 |
Other current assets and asset held for resale | 1.36 | 0.85 | 0.34 |
Total of all assets | 11.69 | 14.7 | 17.81 |
Liabilities £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Short term liabilities | 1.52 | 1.52 | 0.81 |
Long term liabilities | 3.05 | 1.48 | 1.54 |
Other liabilites / pension etc | n/a | n/a | n/a |
Total of all liabilities | 4.57 | 3.01 | 2.35 |
Net assets £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Net assets | 7.12 | 11.7 | 15.46 |
Equity £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Share capital | 11.13 | 11.13 | 11.13 |
Minority interests | n/a | n/a | n/a |
Retained earnings | -18.73 | -13.57 | -10.34 |
Share premium account | 0.71 | 0.71 | 0.71 |
Total equity | 7.12 | 11.7 | 15.46 |
Income £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Turnover | n/a | n/a | n/a |
Operating profit | -5.84 | -3.53 | -0.62 |
Pre-tax profit | -5.93 | -3.64 | -0.72 |